Evolving paradigm of treatment for autoimmune hepatitis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Clinical Immunology

• Publication date

  2017-04-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/1744666X.2017.1319764PMID 28406324
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

  2017cited by this paper
• Hepatic Safety of Maraviroc in Patients with HIV-1 and Hepatitis C and/or B Virus: 144-Week Results from a Randomized, Placebo-Controlled Trial

  2017cited by this paper
• Autoimmune Hepatitis After Liver Transplantation

  2017cited by this paper
• Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions

  2016cited by this paper
• Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis

  2016influential reference
• Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis

  2016cited by this paper
• Targeting Hepatic Fibrosis in Autoimmune Hepatitis

  2016cited by this paper
• Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance.

  2016cited by this paper
• A real‐world study focused on the long‐term efficacy of mycophenolate mofetil as first‐line treatment of autoimmune hepatitis

  2016cited by this paper
• Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

  2016cited by this paper
• Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.

  2016influential reference
• Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases

  2016cited by this paper
• Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury

  2016cited by this paper
• Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis

  2016cited by this paper
• Regulation of Liver Metabolism by Autophagy.

  2016cited by this paper
• Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial

  2016cited by this paper
• Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

  2016cited by this paper
• Adoptive cell transfer in autoimmune hepatitis

  2015cited by this paper
• Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases.

  2015cited by this paper
• Origin and evolution of lysyl oxidases

  2015cited by this paper
• Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences

  2015cited by this paper
• Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis

  2015cited by this paper
• A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation

  2015cited by this paper
• Transitioning from Idiopathic to Explainable Autoimmune Hepatitis

  2015cited by this paper
• Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn’s Disease Mouse Model

  2015cited by this paper
• Incidence and Characteristics of Autoimmune Hepatitis

  2015cited by this paper
• Risk of drug-induced liver injury from tumor necrosis factor antagonists.

  2015cited by this paper
• TrxR1 as a Potent Regulator of the Nrf2-Keap1 Response System

  2015cited by this paper
• Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis.

  2015cited by this paper
• Cell Mediators of Autoimmune Hepatitis and Their Therapeutic Implications

  2015cited by this paper
• Nitric oxide is a potential mediator of hepatic inflammation and fibrogenesis in autoimmune hepatitis

  2015cited by this paper
• Diagnosis and management of autoimmune hepatitis.

  2015cited by this paper
• Vitamin D status is independently associated with plasma glutathione and cysteine thiol/disulphide redox status in adults

  2014cited by this paper
• Progression of autoimmune hepatitis is mediated by IL‐18‐producing dendritic cells and hepatic CXCL9 expression in mice

  2014cited by this paper
• Targeting Apoptosis in Autoimmune Hepatitis

  2014cited by this paper
• Low Serum Vitamin D Levels Are Associated with Severe Histological Features and Poor Response to Therapy in Patients with Autoimmune Hepatitis

  2014cited by this paper
• Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies

  2014cited by this paper
• Functional Roles of Protein Nitration in Acute and Chronic Liver Diseases

  2014cited by this paper
• Hepatic inflammation and progressive liver fibrosis in chronic liver disease.

  2014cited by this paper
• Roles for chemokines in liver disease.

  2014cited by this paper
• Current and prospective pharmacotherapy for autoimmune hepatitis

  2014cited by this paper
• Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis

  2014cited by this paper
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Dysfunctional CD39 Regulatory T Cells and Aberrant Control of T-Helper Type 17 Cells in Autoimmune Hepatitis

  2014cited by this paper
• Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis

  2014cited by this paper
• Role of NADPH Oxidases in Liver Fibrosis

  2014influential reference
• The Nrf2 regulatory network provides an interface between redox and intermediary metabolism.

  2014cited by this paper
• Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets

  2014cited by this paper
• PPARγ Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us?

  2013cited by this paper
• Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.

  2013cited by this paper
• Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.

  2013influential reference
• Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis ‐ a pilot study

  2013influential reference
• Nrf2 Activators Attenuate the Progression of Nonalcoholic Steatohepatitis–Related Fibrosis in a Dietary Rat Model

  2013influential reference
• Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis

  2013influential reference
• Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.

  2013influential reference
• Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents.

  2013cited by this paper
• Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance

  2013influential reference
• Autoimmune hepatitis in southern Israel: A 15‐year multicenter study

  2013cited by this paper
• Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis.

  2013cited by this paper
• Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis

  2013cited by this paper
• Chemokines in tissue fibrosis.

  2013influential reference
• A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.

  2012cited by this paper
• Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs

  2012cited by this paper
• Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

  2012influential reference
• Drug choices in autoimmune hepatitis: Part A – steroids

  2012cited by this paper
• Autoimmune hepatitis after liver transplantation.

  2012cited by this paper
• FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency.

  2012cited by this paper
• Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part II.

  2012cited by this paper
• Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome.

  2012cited by this paper
• Drug choices in autoimmune hepatitis: Part B – nonsteroids

  2012cited by this paper
• Regulatory T cells in autoimmune hepatitis.

  2012cited by this paper
• Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

  2012cited by this paper
• Abatacept for Crohn's disease and ulcerative colitis.

  2012cited by this paper
• Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

  2012cited by this paper
• Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I.

  2012cited by this paper
• The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin‐9/tim‐3 pathway

  2012cited by this paper
• Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

  2011cited by this paper
• TGF-β in progression of liver disease

  2011cited by this paper
• Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy

  2011cited by this paper
• Tissue inhibitors of metalloproteinases

  2011cited by this paper
• The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes

  2011influential reference
• The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort

  2011cited by this paper
• Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model.

  2011cited by this paper
• An additional patient with mycophenolate mofetil embryopathy: Cardiac and facial analyses

  2011cited by this paper
• Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center.

  2011cited by this paper
• Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis

  2011cited by this paper
• Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis.

  2011cited by this paper
• Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

  2011cited by this paper
• Meta‐analysis: antioxidant supplements for liver diseases – the Cochrane Hepato‐Biliary Group

  2010cited by this paper
• Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats

  2010cited by this paper
• Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor β on human intrahepatic fibroblasts cultured in vitro.

  2010cited by this paper
• Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils.

  2010cited by this paper
• Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury.

  2010cited by this paper
• Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.

  2010cited by this paper
• CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation.

  2010cited by this paper
• Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.

  2010influential reference
• Cytochrome P450 2D6 as a Model Antigen

  2010influential reference
• Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation.

  2010cited by this paper
• Emerging Opportunities for Site-Specific Molecular and Cellular Interventions in Autoimmune Hepatitis

  2010cited by this paper
• Major histocompatibility complex class I–related chains A and B (MIC A/B): A novel role in nonalcoholic steatohepatitis

  2010cited by this paper
• Diagnosis and management of autoimmune hepatitis

  2010cited by this paper

• Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis

  2021cites this paper
• Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination

  2020cites this paper
• Otoimmün Hepatit Hastalarında Karaciğer Fibrozisi ile MPV Arasındaki Korelasyon

  2020cites this paper
• Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis

  2019cites this paper
• Autoimmune hepatitis: Current and future therapeutic options

  2019cites this paper
• Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis—authors' reply

  2019cites this paper
• Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis

  2019cites this paper
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases

  2019cites this paper
• Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management

  2018cites this paper
• Rheumatic Manifestations in Autoimmune Liver Disease.

  2018cites this paper
• Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management

  2018cites this paper
• Digestive and Hepatic Aspects of the Rheumatic Diseases.

  2018influential citation
• Autoimmune hepatitis

  2018cites this paper
• Review article: next‐generation transformative advances in the pathogenesis and management of autoimmune hepatitis

  2017influential citation